In oral solid-dose development, sodium fusidate is rarely introduced as a direct compression blend at intended tablet strengths above 250 mg fusidic acid equivalent because the sodium salt is hygroscopic, develops static charge after milling, and can adhere to press feed frames under ambient humidity above 60% RH. Batches held at uncontrolled humidity show agglomeration on the feed frame within 4–8 h, producing fill weight variation in excess of 3% RSD and elevated ejection force. A more robust manufacturing path is dry granulation by roller compaction at roll pressure 4–8 kN/cm, roll speed 5–12 rpm, and granulator screen size 0.8–1.25 mm, followed by blending with microcrystalline cellulose, crospovidone, and sodium starch glycolate. The granulate D50 is typically held between 150 µm and 400 µm, with fines below 20% to preserve die filling on a 16–20 station rotary press. Tablets compressed to hardness 80–120 N show friability below 1.0% under Ph. Eur. 2.9.7, but the dominant failure mode is not mechanical; it is moisture-induced surface tacking during aqueous film coating. When a hypromellose-based coat is applied, inlet air temperature is restricted to 55–65°C and product temperature to 35–42°C; otherwise sodium fusidate can migrate into the coating layer and produce surface roughness. Dissolution testing under USP <711> in pH 6.8 phosphate buffer at paddle speed 50 rpm is used to confirm release, and the development target is typically ≥80% released in 30 min. The acid form of fusidic acid is used in oral tablets only when a dissolution-enhancing step is introduced, such as micronization to a D90 below 20 µm or granulation with a low-melting hydrophilic carrier, because the free acid has low aqueous solubility and dissolution becomes the rate-limiting step.

What Limits Direct Compression of Fusidic Acid at High Drug Load?

Direct compression of the free acid at drug loads above 60% w/w is constrained both by poor aqueous solubility and by the cohesive nature of micronized powder. After air-jet milling, the Hausner ratio often rises above 1.35 and the Carr index above 25%, so the blend does not flow uniformly through the hopper without external vibration. Addition of colloidal silicon dioxide at 0.5–1.0% w/w and pregelatinized starch reduces segregation, but tablets containing 60% free acid still tend to fail content uniformity under USP <905> with acceptance values above 15 if API agglomerates persist above 250 µm. Croscarmellose sodium at 2–4% w/w is preferred over crospovidone in this formulation because wicking into the poorly soluble API pores is more critical than rapid swelling. The dissolution response is highly sensitive to API particle size; a D90 above 40 µm can delay release beyond 80% in 30 min in pH 6.8 phosphate buffer, even when the tablet disintegrates within 15 min under USP <701>. The processing conflict is that micronization improves dissolution but worsens flow and increases the risk of punch sticking, so direct compression is generally reserved for low-dose strengths or development screening, while production-scale batches are moved to dry granulation or ethanol-based wet granulation. When wet granulation is selected, the binder solution is prepared with ethanol or isopropanol rather than purified water to limit moisture uptake by the free acid, and the granulation end point is judged by impeller power consumption rather than by fixed granulation time. This avoids overwetting, which produces hard granules that survive compression but release drug too slowly.

Hard capsule filling with sodium fusidate granulate is performed on a dosator-type encapsulation machine with pin settings adjusted to a compacted slug mass of 300–500 mg for common dose strengths, depending on the ratio of granulate to filler. The granulate moisture content must be controlled below 2.0% LOD before encapsulation; granulate conditioned at 40% RH for 24 h shows reduced tack on the tamping pins and fewer split plugs during transfer. Gelatin capsule shells are less suitable than HPMC when the fill moisture exceeds 2.5%, because the shell can become brittle and crosslinking may occur under accelerated storage. Encapsulation speed above 60,000 capsules/h on a continuous machine can increase fill weight variability if the granulate contains excessive fines; therefore the fraction below 75 µm is maintained below 15% by sieve analysis. Fill weight uniformity is checked at intervals under USP <905>, and disintegration of the filled capsules is evaluated in 0.1 N hydrochloric acid for 15 min under USP <701>. Because sodium fusidate is water-soluble, release from capsules is usually rapid once the shell opens; the critical quality attributes are therefore content uniformity and moisture-induced physical instability rather than dissolution failure. Capsule formulations often include lactose monohydrate or dibasic calcium phosphate dihydrate as filler, but the latter must be evaluated for compatibility because calcium ions can interact with fusidic acid under certain pH conditions.

Aqueous Granulation of Sodium Fusidate Increases Residual Moisture and Modifies Suspension Viscosity

High-shear wet granulation of sodium fusidate in a vertical granulator with impeller speed 200–400 rpm and chopper speed 1500–3000 rpm, using purified water or an aqueous povidone binder solution, produces granules with a D50 of 180–350 µm after fluid-bed drying at 50–65°C inlet air. Residual moisture is targeted below 1.5% LOD because sodium fusidate releases bound water slowly and the granule bed can cake in storage if this limit is exceeded. Granules are filled into sachets or bottles for reconstitution; upon addition of purified water, sedimentation behaviour depends on the concentration of xanthan gum, which is typically varied between 0.2% and 0.5% w/v, and on the granule size distribution. Viscosity measured by a Brookfield spindle rheometer at 25°C and 50 rpm is maintained between 50 mPa·s and 150 mPa·s to allow dose uniformity after shaking without making the suspension too viscous to pour. Published data linking spindle speed and sodium fusidate granule concentration for this exact formulation matrix is limited; viscosity must therefore be mapped experimentally on a batch-specific basis, and the method should be validated under Ph. Eur. 2.2.10 or an equivalent rotational viscometer procedure. The preservative system, if used, must be challenged according to Ph. Eur. 5.1.3 because adsorption onto sodium fusidate granule surfaces or complexation with the suspending polymer can reduce antimicrobial activity. Taste masking is handled with sucralose or sorbitol and a fruit flavour, because the API has a bitter taste that reduces patient compliance in pediatric and elderly populations; the final reconstituted suspension is targeted to deliver a dose of 250 mg/5 mL fusidic acid equivalent, and the bottle is fitted with a graduated oral syringe or measuring cup to minimise dosing error under the applicable pharmacopoeial dose delivery method.

When Sodium Fusidate Is Formulated as a Buffered Intravenous Infusion

Reconstitution of lyophilized sodium fusidate for intravenous use begins with a buffered diluent rather than direct addition to normal saline, because the free acid has low solubility below about pH 6 and can precipitate in acidic media. The sterile powder or lyophilized cake is first reconstituted with a phosphate–citrate buffer to a pH of 7.4–7.6, then further diluted in 0.9% sodium chloride or 5% glucose to the prescribed infusion volume. Direct mixing with calcium-containing solutions is not assumed to be compatible; if the infusion line contains residual calcium or magnesium, a visible precipitate may form because fusidic acid can form poorly soluble salts with polyvalent cations, and published data for this specific configuration is limited, so a dedicated physicochemical compatibility test under USP <788> or Ph. Eur. 2.9.19 is required before routine co-administration. The reconstituted solution is inspected visually and passed through a 0.2 µm in-line filter during administration to retain particulate matter. Subvisible particle counts are measured by light obscuration; for small-volume parenterals, the limits are applied as defined in USP <788>, and the product must also meet sterility under USP <71> and bacterial endotoxin limits under USP <85>. Aqueous solutions of fusidate sodium are not autoclaved as a terminal step unless stability data demonstrate no degradation; the more common route is aseptic filling of the sterile powder followed by lyophilization, because the molecule is hydrolytically labile in water and the process must limit both heat and moisture. When moist heat terminal sterilization is evaluated, a cycle of 121°C for 15 min is used as a reference; the decision is governed by ICH Q8 quality-by-design and the pharmacopoeial sterility assurance criteria rather than by a single fixed cycle. The infusion admixture should be used within 24 h when stored at 2–8°C unless stability data support a longer hold time, and the pH of the admixture should not be allowed to fall below 6.0 during preparation.

Across the oral and injectable dosage forms, the release and control strategy is defined by the following matrix; the acceptance criteria are drawn from current pharmacopoeial chapters and ICH guidelines rather than from a single generic specification, because the critical failure modes differ between a hygroscopic oral granulate and a sterile lyophilized powder.

Aseptic filling of sodium fusidate sterile powder into molded or tubing vials is conducted in a Grade A environment under EU GMP Annex 1 and ISO 14644-1 class ISO 5 conditions, with a surrounding Grade B area and validated vaporised hydrogen peroxide decontamination cycles of 30–60 min for the isolator. The powder is often filled as a compacted cake or lyophilized after filling from an aqueous solution; when lyophilization is used, the cycle includes freezing to −40°C, primary drying at shelf temperatures from −20°C to 0°C with chamber pressure 80–150 µbar, and secondary drying at 25–40°C for 4–8 h until the moisture endpoint is below 1.0% by Karl Fischer titration. The lyophilized cake is required to reconstitute to a clear or slightly opalescent solution within 2 min after adding the buffer; if reconstitution is slow, the cake structure may have collapsed due to insufficient primary drying or an inappropriate excipient ratio. Container closure integrity is verified by helium leak detection or dye ingress under USP <1207>, and residual moisture is monitored as a stability-critical factor because fusidate sodium hydrolyses slowly in the presence of free water. The sterile powder is stored below 25°C in a light-protective container, and the reconstituted solution is not held for extended periods unless supported by stability data. This final application scenario is governed more by environmental control and moisture exclusion than by formulation complexity, but the interaction between lyophilization cycle design and cake quality is the principal source of batch-to-batch variance.